These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22253862)

  • 1. Effect of vaccines and antivirals during the major 2009 A(H1N1) pandemic wave in Norway--and the influence of vaccination timing.
    Blasio BF; Iversen BG; Tomba GS
    PLoS One; 2012; 7(1):e30018. PubMed ID: 22253862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway.
    Guzmán Herrador BR; Aavitsland P; Feiring B; Riise Bergsaker MA; Borgen K
    BMC Infect Dis; 2012 Mar; 12():63. PubMed ID: 22429643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
    Ahmed SS; Schur PH; MacDonald NE; Steinman L
    J Autoimmun; 2014 May; 50():1-11. PubMed ID: 24559657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling optimal age-specific vaccination strategies against pandemic influenza.
    Lee S; Golinski M; Chowell G
    Bull Math Biol; 2012 Apr; 74(4):958-80. PubMed ID: 22147102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Field effectiveness of pandemic and 2009-2010 seasonal vaccines against 2009-2010 A(H1N1) influenza: estimations from surveillance data in France.
    Pelat C; Falchi A; Carrat F; Mosnier A; Bonmarin I; Turbelin C; Vaux S; van der Werf S; Cohen JM; Lina B; Blanchon T; Hanslik T
    PLoS One; 2011 May; 6(5):e19621. PubMed ID: 21573005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prioritization of delayed vaccination for pandemic influenza.
    Shim E
    Math Biosci Eng; 2011 Jan; 8(1):95-112. PubMed ID: 21361402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a MF-59™-adjuvanted pandemic influenza vaccine to prevent 2009 A/H1N1 influenza-related hospitalisation; a matched case-control study.
    Steens A; Wijnans EG; Dieleman JP; Sturkenboom MC; van der Sande MA; van der Hoek W
    BMC Infect Dis; 2011 Jul; 11():196. PubMed ID: 21767348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009--a comparison of two methods; Germany, 2009/10.
    Uphoff H; An der Heiden M; Schweiger B; Campe H; Beier D; Helmeke C; Littmann M; Haas W; Buda S; Faensen D; Feig M; Altmann D; Wichmann O; Eckmanns T; Buchholz U
    PLoS One; 2011; 6(7):e19932. PubMed ID: 21789163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.
    Banzhoff A; Haertel S; Praus M
    Hum Vaccin; 2011 May; 7(5):539-48. PubMed ID: 21422814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010).
    Hanquet G; Van Damme P; Brasseur D; De Cuyper X; Gregor S; Holmberg M; Martin R; Molnár Z; Pompa MG; Snacken R; van der Sande M; Van Ranst M; Wirtz A; Neels P
    Vaccine; 2011 Jan; 29(3):370-7. PubMed ID: 21075164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in risk for narcolepsy over time and impact of definition of onset date following vaccination with AS03 adjuvanted pandemic A/H1N1 influenza vaccine (Pandemrix) during the 2009 H1N1 influenza pandemic.
    Granath F; Gedeborg R; Smedje H; Feltelius N
    Pharmacoepidemiol Drug Saf; 2019 Aug; 28(8):1045-1053. PubMed ID: 31062443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.
    Nolan T; Roy-Ghanta S; Montellano M; Weckx L; Ulloa-Gutierrez R; Lazcano-Ponce E; Kerdpanich A; Safadi MA; Cruz-Valdez A; Litao S; Lim FS; de Los Santos AM; Weber MA; Tinoco JC; Mezerville MH; Faingezicht I; Kosuwon P; Lopez P; Borja-Tabora C; Li P; Durviaux S; Fries L; Dubin G; Breuer T; Innis BL; Vaughn DW
    J Infect Dis; 2014 Aug; 210(4):545-57. PubMed ID: 24652494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High prevalence of antibodies to the 2009 pandemic influenza A(H1N1) virus in the Norwegian population following a major epidemic and a large vaccination campaign in autumn 2009.
    Waalen K; Kilander A; Dudman SG; Krogh GH; Aune T; Hungnes O
    Euro Surveill; 2010 Aug; 15(31):. PubMed ID: 20738992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
    Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009.
    Skowronski DM; Janjua NZ; De Serres G; Hottes TS; Dickinson JA; Crowcroft N; Kwindt TL; Tang P; Charest H; Fonseca K; Gubbay JB; Bastien N; Li Y; Petric M
    BMJ; 2011 Feb; 342():c7297. PubMed ID: 21292718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Planning for the next influenza H1N1 season: a modelling study.
    Carrat F; Pelat C; Levy-Bruhl D; Bonmarin I; Lapidus N
    BMC Infect Dis; 2010 Oct; 10():301. PubMed ID: 20964814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England.
    Andrews N; Waight P; Yung CF; Miller E
    J Infect Dis; 2011 Jan; 203(1):32-9. PubMed ID: 21148494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epilepsy in Children After Pandemic Influenza Vaccination.
    Håberg SE; Aaberg KM; Surén P; Trogstad L; Ghaderi S; Stoltenberg C; Magnus P; Bakken IJ
    Pediatrics; 2018 Mar; 141(3):. PubMed ID: 29449342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe.
    Romio S; Weibel D; Dieleman JP; Olberg HK; de Vries CS; Sammon C; Andrews N; Svanström H; Mølgaard-Nielsen D; Hviid A; Lapeyre-Mestre M; Sommet A; Saussier C; Castot A; Heijbel H; Arnheim-Dahlström L; Sparen P; Mosseveld M; Schuemie M; van der Maas N; Jacobs BC; Leino T; Kilpi T; Storsaeter J; Johansen K; Kramarz P; Bonhoeffer J; Sturkenboom MC
    PLoS One; 2014; 9(1):e82222. PubMed ID: 24404128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Report of the 7th meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials, World Health Organization, Geneva, 17-18 February 2011.
    Girard MP; Katz JM; Pervikov Y; Hombach J; Tam JS
    Vaccine; 2011 Oct; 29(44):7579-86. PubMed ID: 21856358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.